Naslov
“Pharmacogenomic testing in the era of patient tailored HCV treatment”

Autori
Smolić, Martina

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
3rd International Monothematic Conference on Viral Hepatitis C (IMC-HCV-2016) / - , 2016

Skup
3rd International Monothematic Conference on Viral Hepatitis C (IMC-HCV-2016)

Mjesto i datum
Orahovica, Hrvatska, 29.09.2016. - 01.10.2016

Vrsta sudjelovanja
Pozvano predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Viral Hepatitis C; HCV infection

Sažetak
Treatment of Hepatitis C virus infection can be complex, and can depend on many factors such as virus genotype, severity of symptoms, and condition of the liver. The newer direct acting antivirals (DAAs) have begun to dominate the Hepatitis C treatment market. These medications can cure HCV infection at higher rates, with lower incidence of ADRs, and in a half the course of treatment compared to the traditional drug regimes. However, this new class of treatment is much more expensive than the traditional treatment options justifying the use of pharmacogenomic testing in the clinical setting. As well as in the other areas, implemetation of the pharmacogenomic testing in the HCV treatment is also faced with considerable challenges. DAAs in the treatment of HCV infection as well as pharmacogenetic testings currently used to tailor available treatment options in adition to HCV genotype, previous treatment status, and degree of progression will be disscussed.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti

POVEZANOST RADA